AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28258263 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music distraction group
Number of subjects: 60
Study 28258263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26096296 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/capecitabine (TX)
Number of subjects: 206
Study 26096296 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/capecitabine (NX)
Number of subjects: 206
Study 22925088 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) without grafting material (test group)
Number of subjects: 12
Study 22925088 — intervention group
Group type: COMPARATOR
Intervention: Osteotome sinus floor elevation (OSFE) with grafting material (control group)
Number of subjects: 12
Study 21672217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 180
Study 21672217 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 180
Study 21672217 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 180
Study 19348819 — intervention group
Group type: EXPERIMENTAL
Intervention: Blankets warmed to 110 degrees F (43 degrees C)
Number of subjects: 3
Study 19348819 — intervention group
Group type: EXPERIMENTAL
Intervention: Blankets warmed to 150 degrees F (66 degrees C)
Number of subjects: 3
Study 19348819 — intervention group
Group type: COMPARATOR
Intervention: Unheated blankets
Number of subjects: 3
Study 16813590 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal cancer surgery
Number of subjects: 0
Study 16813590 — intervention group
Group type: COMPARATOR
Intervention: Open rectal cancer surgery
Number of subjects: 0
Study 14752411 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm of inhaled nitric oxide
Number of subjects: 29
Study 14752411 — intervention group
Group type: COMPARATOR
Intervention: No additional inhalatory treatment
Number of subjects: 29
Study 11045858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 3962
Study 11045858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 3962
Study 11045858 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal status
Number of subjects: 3962
Study 11045858 — intervention group
Group type: COMPARATOR
Intervention: Fertile stage
Number of subjects: 3962
Study 11045858 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-CDT
Number of subjects: 3962
Study 9206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate 5 mg daily per os
Number of subjects: 56
Study 9206771 — intervention group
Group type: COMPARATOR
Intervention: Didrogesteron 10 mg twice a day per os
Number of subjects: 56
Study 8320052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement taken daily for 4 months
Number of subjects: 0
Study 8320052 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken daily for 4 months
Number of subjects: 0
Study 8320052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement
Number of subjects: 0
Study 8320052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field irradiation followed by a boost to the prostate
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal management prior to or during radiotherapy
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum acid phosphatase elevation
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal status
Number of subjects: 566
Study 3558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant hormonal management
Number of subjects: 566
Study 31022105 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ + LST
Number of subjects: 91
Study 31022105 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ + HST
Number of subjects: 91
Study 31022105 — intervention group
Group type: EXPERIMENTAL
Intervention: LST
Number of subjects: 91
Study 31022105 — intervention group
Group type: EXPERIMENTAL
Intervention: HST
Number of subjects: 91
Study 31022105 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ
Number of subjects: 91
Study 29926912 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 and 0.2 μg/kg/min)
Number of subjects: 31
Study 29926912 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (0.4 and 0.8 μg/kg/min)
Number of subjects: 31
Study 27305903 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132
Study 27305903 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CCBT)
Number of subjects: 132
Study 27305903 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline DSE
Number of subjects: 132
Study 27305903 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in DSE with treatment
Number of subjects: 132
Study 25715558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicanalicular Mini‐Monoka and Monoka stents
Number of subjects: 151
Study 25715558 — intervention group
Group type: COMPARATOR
Intervention: Bicanalicular SRS and Ritleng stents
Number of subjects: 151
Study 22271284 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation SLP (T‐SLP)
Number of subjects: 40
Study 20665514 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex) administered every 3 weeks for up to 24 weeks
Number of subjects: 117
Study 20665514 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 3 weeks for up to 24 weeks
Number of subjects: 117
Study 18520504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue (Tisseel)
Number of subjects: 24
Study 18520504 — intervention group
Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 24
Study 15777301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% alone
Number of subjects: 60
Study 15777301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% plus 10 microg sufentanil
Number of subjects: 60
Study 15777301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% plus 20 microg sufentanil
Number of subjects: 60
Study 15777301 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ropivacaine 1% alone)
Number of subjects: 60
Study 12481972 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Family Intervention (EBFI)
Number of subjects: 87
Study 12481972 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Family Intervention (SBFI)
Number of subjects: 87
Study 12481972 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 87
Study 12481972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BFI programs (EBFI and SBFI)
Number of subjects: 87
Study 10726441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormonal therapy with 50 micrograms of ethynilestradiol and 5 mg of MAP
Number of subjects: 30
Study 10726441 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 30
Study 7718318 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 15 mg/m2 intravenously (i.v.) and prednisone 60 mg/m2 oral days 1‐4 (MP)
Number of subjects: 406
Study 7718318 — intervention group
Group type: COMPARATOR
Intervention: VBAMDex (vincristine/BCNU/doxorubicin/melphalan/dexamethasone)
Number of subjects: 406
Study 7718318 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha (5 x 10(6) IU, subcutaneous (S.C.) 3 times per week)
Number of subjects: 406
Study 7718318 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 406
Study 1818628 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic concept including effective motivation; specific details on dosage and duration not available.
Number of subjects: 0
Study 7445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76% (ionic contrast medium)
Number of subjects: 16
Study 7445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (22.5 mEq/l)
Number of subjects: 16
Study 7445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (33.75 mEq/l)
Number of subjects: 16
Study 7445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76%
Number of subjects: 16
Study 7445641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (higher volumes)
Number of subjects: 16
Study 30997482 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention targeting weight loss
Number of subjects: 319
Study 30997482 — intervention group
Group type: COMPARATOR
Intervention: Control condition of diabetes support and education
Number of subjects: 319
Study 31061515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 8 weeks
Number of subjects: 0
Study 31061515 — intervention group
Group type: COMPARATOR
Intervention: Active control training (CT)
Number of subjects: 0
Study 31061515 — intervention group
Group type: COMPARATOR
Intervention: One-time mindfulness induction (MI)
Number of subjects: 0
Study 28634320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular block (CIAB)
Number of subjects: 54
Study 28634320 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 54
Study 25887469 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of glucocorticoids
Number of subjects: 116
Study 24299218 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifecta valve (St. Jude Medical)
Number of subjects: 0
Study 24299218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitroflow valve (Sorin Group)
Number of subjects: 0
Study 24299218 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards Magna Ease valve (Edwards Lifesciences)
Number of subjects: 0
Study 21425506 — intervention group
Group type: EXPERIMENTAL
Intervention: neosaxitoxin (neoSTX)
Number of subjects: 137
Study 21425506 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 137
Study 19715043 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control expectancies through smoking
Number of subjects: 117
Study 19715043 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about weight gain upon cessation
Number of subjects: 117
Study 17729399 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit (twice daily for 4 weeks)
Number of subjects: 33
Study 15056829 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 63
Study 15056829 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 10 mg/day
Number of subjects: 63
Study 12233807 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy (4 leeches applied topically at painful periarticular sites)
Number of subjects: 16
Study 12233807 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for pain (excluding nonsteroidal anti-inflammatory drugs)
Number of subjects: 16
Study 9848971 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal approach
Number of subjects: 0
Study 9848971 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter
Number of subjects: 0
Study 9848971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8010369 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating time schedule of bright light treatment
Number of subjects: 31
Study 8010369 — intervention group
Group type: COMPARATOR
Intervention: Fixed morning schedule of bright light treatment
Number of subjects: 31
Study 8010369 — intervention group
Group type: COMPARATOR
Intervention: Fixed evening schedule of bright light treatment
Number of subjects: 31
Study 2671449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (2.5 mg once a day, increased to 5-10 mg per day for 12 weeks)
Number of subjects: 149
Study 2671449 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine or Atenolol (control)
Number of subjects: 149
Study 1098807 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclamped group
Number of subjects: 41
Study 1098807 — intervention group
Group type: COMPARATOR
Intervention: Clamped group
Number of subjects: 41
Study 31021265 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic whole-body vibration (NWBV) group (n=11)
Number of subjects: 31
Study 31021265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic whole-body vibration (HWBV) group (n=10)
Number of subjects: 31
Study 31021265 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 31
Study 28403644 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 129
Study 28403644 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 129
Study 25415245 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) + Scaling and Root Planing (SRP)
Number of subjects: 20
Study 25415245 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) only
Number of subjects: 20
Study 23233423 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated framework for identifying medication overuse
Number of subjects: 200
Study 23233423 — intervention group
Group type: COMPARATOR
Intervention: Manual review by two gastroenterologists
Number of subjects: 200
Study 21241987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 207
Study 21241987 — intervention group
Group type: COMPARATOR
Intervention: Azelnidipine
Number of subjects: 207
Study 18280939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (Chx)
Number of subjects: 80
Study 18280939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate with 0.15% benzydamine hydrochloride (Chx+Bzd)
Number of subjects: 80
Study 18280939 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% polyvinylpyrrolidone iodine (Pvp)
Number of subjects: 80
Study 18280939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine hydrochloride (Bzd)
Number of subjects: 80
Study 18280939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile saline solution (Ss)
Number of subjects: 80
Study 15854874 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire measure of the relative reinforcing value of snack food versus fruits and vegetables (condition 1)
Number of subjects: 49
Study 15854874 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire measure of the relative reinforcing value of snack food (Study 2)
Number of subjects: 49
Study 12543740 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video (4.5 minute audiovisual presentation)
Number of subjects: 244
Study 12543740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 244
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in men
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in women
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with higher salary grade
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and hypertension in women
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant variables for systolic blood pressure
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant variables for diastolic blood pressure
Number of subjects: 998
Study 10805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of hypertension
Number of subjects: 998
Study 9132505 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (125 mg)
Number of subjects: 0
Study 9132505 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch (control)
Number of subjects: 0
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms hepatitis B vaccine
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms hepatitis B vaccine
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram hepatitis B vaccine
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anti-HBs titres (10-100 miu/mL)
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium anti-HBs titres (101-1000 miu/mL)
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: High anti-HBs levels (greater than 1000 miu/mL)
Number of subjects: 267
Study 1535229 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural booster response
Number of subjects: 267
Study 6707051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g gentamicin base per 40 g pack of powdered polymer
Number of subjects: 30
Study 6707051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g gentamicin base per 40 g pack of powdered polymer
Number of subjects: 30
Study 29952235 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw Dynasplint
Number of subjects: 40
Study 29952235 — intervention group
Group type: COMPARATOR
Intervention: Conventional stretching
Number of subjects: 40
Study 27454492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention using developed CD-ROMs and interactive sessions
Number of subjects: 40
Study 24001275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary (uninterrupted sitting)
Number of subjects: 20
Study 24001275 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks (sitting interrupted with a 2 min light-intensity walk break every 20 min)
Number of subjects: 20
Study 24001275 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks+PA (sitting interrupted with a 2 min light-intensity walk break every 20 min and 2 × 20 min of moderate-intensity PA)
Number of subjects: 20
Study 22675960 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg/kg IV with propofol 0.7 mg/kg IV
Number of subjects: 60
Study 22675960 — intervention group
Group type: COMPARATOR
Intervention: ketamine 0.5 mg/kg IV with propofol 0.7 mg/kg IV
Number of subjects: 60
Study 20367516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (6 sessions, once weekly for 30 min over 6-8 weeks)
Number of subjects: 13
Study 20367516 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (control group)
Number of subjects: 13
Study 18586313 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 level measurement using Centocor CA-125II RIA assay
Number of subjects: 25608
Study 18586313 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 level measurement
Number of subjects: 25608
Study 18586313 — intervention group
Group type: EXPERIMENTAL
Intervention: Current hormone therapy use
Number of subjects: 25608
Study 15791969 — intervention group
Group type: COMPARATOR
Intervention: Conventional tension‐free meshplasty
Number of subjects: 50
Study 15791969 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair through a single 2‐cm to 2.5‐cm skin incision with laparoscopic assistance
Number of subjects: 50
Study 12482559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 186
Study 12482559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 186
Study 12482559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 10680388 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture training and TMD self-management instructions
Number of subjects: 60
Study 10680388 — intervention group
Group type: COMPARATOR
Intervention: TMD self-management instructions only
Number of subjects: 60
Study 9493481 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0
Study 9493481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 9493481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8446743 — intervention group
Group type: EXPERIMENTAL
Intervention: E (epinephrine) 82 pmol/kg/min
Number of subjects: 10
Study 8446743 — intervention group
Group type: EXPERIMENTAL
Intervention: NE (norepinephrine) 178 pmol/kg/min
Number of subjects: 10
Study 8446743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 5.4 ml/hr)
Number of subjects: 10
Study 3011834 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment group (L-T4 1.5 micrograms/kg iv daily for 2 weeks)
Number of subjects: 23
Study 3011834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T4 treatment)
Number of subjects: 23
Study 3011834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (survivors and nonsurvivors)
Number of subjects: 23
Study 29691923 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% homatropine with hyperopic defocus (‐3.00 D)
Number of subjects: 30
Study 29691923 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hyperopic defocus (‐3.00 D)
Number of subjects: 30
Study 29691923 — intervention group
Group type: COMPARATOR
Intervention: Placebo with myopic defocus (+3.00 D)
Number of subjects: 30
Study 29691923 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% homatropine with myopic defocus (+3.00 D)
Number of subjects: 30
Study 29691923 — intervention group
Group type: EXPERIMENTAL
Intervention: Homatropine alone
Number of subjects: 30
Study 27641143 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg subcutaneous injections monthly for 12 months)
Number of subjects: 7180
Study 27641143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections monthly for 12 months)
Number of subjects: 7180
Study 27641143 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (after transition to denosumab)
Number of subjects: 7180
Study 27641143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after transition to denosumab)
Number of subjects: 7180
Study 24828268 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PrEP
Number of subjects: 4747
Study 24828268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4747